Active broad-market exchange-traded funds at the close of Wednesday's regular session:
SPDR S&P 500 ( SPY ): -0.66%
iShares S&P 500 ( IVV ): -0.66%
PowerShares QQQ ( QQQ ): -0.69%
iShares Russell 2000 ( IWM ): -1.02%
iShares Russell 1000 Growth ( IWF ): -0.59%
iShares MSCI Emerging Markets Index (EEM): -0.69%
United States Oil Fund (USO): +0.65%
SPDR Gold Shares (GLD): -0.87%
Select Financial Sector SPDRS (XLF): -1.38%
Pre-Market Movers
SPY, -0.17%
EEM, -0.51%
XLF, -0.37%
VXX, +0.16%
GDX, +0.04%
Broad Market Indicators
Most broad-market exchange-traded funds, including SPY, IWM, IVV edged lower. Actively traded PowerShares QQQ ( QQQ ) was down 0.31%.
U.S. stocks are looking to open Thursday's session in the red following the report that weekly jobless claims fell by 3,000 to 336,000 - a narrower decline that the drop to a seasonally adjusted 335,000 that economists were expecting. In other data, consumer prices rose 0.1% in January, in line with forecasts; core CPI also rose 0.1%, just slightly below the expected increase by 0.2%.
Power Play: Consumer
Consumer Staples Select Sector SPDR (XLP), Vanguard Consumer Staples ETF (VDC) and iShares Dow Jones US Consumer Goods (IYK) were unchanged pre-market after a weaker session Wednesday.
Among stocks, Tesla Motors Inc. ({TSLA) was up 12% after it reported non-GAAP EPS of $0.33, exceeding the Wall Street consensus estimate of $0.21. The company also said it will deliver 35,000 Model S vehicles in 2014, an increase of 55% from last year.
Winners and Losers
Financial
Select Financial Sector SPDRs (XLF) was down 0.37% pre-bell. Direxion Daily Financial Bull 3X shares (FAS) was down 0.92%. Its bearish counterpart, FAZ, was up 0.59%.
Among financial stocks, Blackhawk Network Holdings (HAWK) was down more than 14% pre-bell after it reported late Wednesday that Q4 GAAP earnings were $0.92, an increase of 31% from $0.70 from a year prior. Adjusted EPS was $0.81, up 13% from $0.72 per share posted in the year ago quarter. Operating revenues totaled $521.2 million, an increase of 15% from $452.9 million. The analyst consensus on Capital IQ called for earnings of $0.84 per share on revenue of $539.4 million.
Technology
Technology Select Sector SPDR ETF (XLK), iShares Dow Jones US Technology ETF (IYW), iShares S&P North American Technology ETF (IGM) and iShares S&P North American Technology-Software Index (IGV) were flat after seeing gains in Wednesday's session. SPDR S&P International Technology Sector ETF (IPK) was also quiet in pre-market.
Among semiconductor ETFs, SPDR S&P Semiconductor (XSD) and Semiconductor Sector Index Fund (SOXX) were flat as well.
In stocks news, Sonus Networks (SONS) was up about 2% pre-market after it reported Q4 revenue of $76.2 million, ahead of the analyst consensus of $72.6 million on Capital IQ. EPS was $0.02, in line with expectations. For Q1, the company guided for revenue of $70 million and a loss of $0.01 per share. The Street view is $65.4 million in revenue and a loss of $0.01 per share.
Energy
Dow Jones U.S. Energy Fund (IYE) and Energy Select Sector SPDR (XLE) were both unchanged pre-bell.
In corporate news, Denbury Resources (DNR) was down 2% after it reported adjusted net income of $100 million for Q4 of 2013, or $0.27 per diluted share. That's short of the $0.31 per share Street view, according to Capital IQ estimates. Revenue was $596 million, versus the Street's expected $610 million in revenue.
Commodities
Crude was down 0.46%; United States Oil Fund (USO) was down 0.46%. Natural gas was down 0.83% and United States Natural Gas Fund (UNG) was up 0.78%.
Gold and silver both fell in pre-market trading, down 0.7% and 1.46% respectively. Among rare metal funds, SPDR Gold Trust (GLD) was down 0.01% and iShares Silver Trust (SLV) edged up 0.15%.
Healthcare
Health Care SPDR (XLV), Vanguard Health Care ETF (VHT) and iShares Dow Jones US Healthcare (IYH) were flat after reaching record highs in the previous session. Biotech ETF iShares NASDAQ Biotechnology Index (IBB) was down 0.03%.
In corporate news, Raptor Pharmaceutical (RPTP) was up 36.13%, on track to set a record high in regular trading, after the company announced positive results from a trial of RP103 for the potential treatment of Huntington's disease. Analysis of all 96 patients enrolled in the trial showed a positive trend towards slower progression of Total Motor Score (TMS) in patients treated with RP103 vs. those patients on placebo, which was the primary endpoint of the study.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
